Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, said it will present at the 2025 Annual Meeting of the Parkinson Study Group, held Dec. 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson’s biomarker results showing that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap, which also reduces tau biomarkers linked to disease progression. Annovis will also debut a cross-study comparison of all completed trials, offering the most comprehensive view to date of cognitive outcomes across indications and underscoring that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the Company’s strategic path forward.
To view the full press release, visit https://ibn.fm/xiBPL
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN